Background. Despite much evidence that modifying risk factors for coronary heart disease can decrease morbidity and mortality, little is known about the impact of risk-factor modification on life expectancy.
lic health campaigns, as exemplified by the fact that the American Medical Association has "declared war on cholesterol." 8 To date, however, there is little information on the impact of risk factor modification on life expectancy. How much would life expectancy be prolonged if Americans stop smoking, lower their serum cholesterol levels, control their blood pressures, or lose weight? Using the Coronary Heart Disease Policy Model,9-12 a computer simulation of CHD in the US population, we have forecasted potential gains in both population-wide and individual life expectancy from various risk factor modifications for the cohort of Americans turning age 35 years in 1990.
Methods

The Model
The Coronary Heart Disease Policy Model9-12 is a state-transition computer simulation model that consists of three submodels: the Demographic-Epidemiologic Submodel, the Bridge Submodel, and the Disease History Submodel (Figure 1 ).
The Demographic-Epidemiologic Submodel assesses each individual's risk of developing CHD based on age, sex, smoking status (no, yes; if yes, average number of cigarettes per day), diastolic blood pressure (.94 mm Hg, 95-104 mm Hg, >105 mm Hg), relative weight (.109% of ideal, 110-129% of ideal, >130% of ideal), and serum cholesterol level (.249 mg/dl, 250-299 mg/dl, .300 mg/dl). Based on the categories for each of these factors, the entire US population age 35-84 is divided into 5,400 cells, each with a specific value for each factor. For simplicity, the model's outputs are collapsed into 10-year age ranges, thus yielding 540 strata.
For the current analyses, subjects turning age 35 years in 1990 who are free of clinical coronary heart disease enter the Demographic-Epidemiologic Submodel. That cohort is then followed for 50 years during which, in any given year, persons may 1) develop clinical CHD (in which case they move to the Bridge Submodel, 2) age by 1 year without developing CHD and proceed to the subsequent year's cell in the Demographic-Epidemiologic Submodel, 3) die of other causes, or 4) turn age 85 years and exit the model.
The Bridge Submodel characterizes subjects for the first 30 days after they develop CHD, and the Disease History Submodel considers all events that occur to such persons after that 30-day period: interventions such as coronary artery bypass surgery, recurrent CHD events, CHD deaths, and deaths from other causes.
Assumptions of the Model
The Demographic-Epidemiologic Submodel was initially constructed using the 1980 US census13 and the estimated proportion of persons without CHD.14 The distribution of smoking status, diastolic blood pressure, relative weight, and serum cholesterol level in the US For each of the 540 cells, relative risk (,l) coefficients for CHD incidence and for total mortality were based on data from the Framingham Heart Study. 3 We obtained the age-and gender-specific coefficients for all risk factors in the Demographic-Epidemiologic Submodel from the Framingham Heart Study's 30year follow-up. We then smoothed these raw coefficients by age for each gender with a weighted leastsquares regression of the Framingham coefficients on the midpoint of each 10-year age interval, where the weights represented the inverse of the coefficients' standard errors. CHD incidence rates for ages 35-74 years were based on the Framingham Heart Study18 with a secular adjustment for the decline in CHD incidence19 since the beginning of the Framingham Heart Study and with extrapolation to ages 75-84 years and linear interpolation to smooth the agespecific annual rates.9 Mortality rates for CHD and other causes were based on US vital statistics and were assumed to apply to a population with risk factors distributed according to the HANES data.
The Disease History Submodel tracks the cohort of patients who survive the first month after their CHD event (i.e., graduates of the Bridge Submodel) through 12 states. These patients with CHD are categorized according to their previous history: whether they are in their first or subsequent year after the initial event and whether their history includes one or more cardiac arrests. one or more myocardial infarctions, one or more coronary artery bypass graft operations, any combination of these, or none of these (i.e., angina only). Each of the 12 resulting states is further subclassified by age and gender, making a total of 1,200 Disease History cells (50 ages x 2 genders x 12 CHD states).
During each model year, patients in the Disease History Submodel face the chance of having a cardiac arrest, a myocardial infarction, or a coronary artery bypass operation (or any combination of these). Each event has a specific case-fatality rate tailored to the cell in which the person started that year. Methods used to calculate these event rates are described in detail elsewhere.9 Survivors of a given year begin the next year in the appropriate Disease History cell.
Interventions
Risk factor interventions, such as reductions in diastolic blood pressure, are simulated interactively with the Coronary Heart Disease Policy Model. Primary interventions, that is, interventions aimed at preventing CHD in persons with no history of CHD, are simulated by adjusting the Demographic-Epidemiologic Submodel. The user can adjust risk factors by a relative amount (e.g., a 10% reduction in cholesterol), adjust risk factors by an absolute amount (e.g., a 5-mm Hg decrease in diastolic blood pressure), or redefine the mean value (e.g., change the mean number of cigarettes smoked per day from 12 to zero) for any or all cells. In the Demographic-Epidemiologic Submodel, the probability of dying from causes other than CHD is a function of not only age and gender but also diastolic blood pressure and mean number of cigarettes smoked; thus, by adjusting diastolic blood pressure or smoking, one simultaneously adjusts the risk of developing CHD and of dying from non-CHD causes.
We simulated secondary prevention (of recurrence of CHD events) by reducing the following Disease History probabilities: the probability of an arrest, myocardial infarction, or coronary artery bypass operation given a history of angina, arrest, myocardial infarction, or coronary artery bypass operation; and the mortality rate from chronic coronary artery disease. We determined the percent reductions for these variables as follows: First, at the midpoint of each 10-year age interval, that is, at ages 40, 50, 60, 70, and 80 years, we used the frequency distribution and the mean risk factor values in the Demographic-Epidemiologic Submodel for persons having their first CHD "event" (angina, myocardial infarction, or cardiac arrest with or without myocardial infarction). To calculate a percent reduction in CHD risk from a given intervention, we applied those values to the formula % decrease in CHD risk = (1-e-PA)x 100 where ,B represents the relative risk coefficient for CHD incidence and A is the difference between the preintervention and postintervention risk factor values.
For example, among 35to 44-year-old women developing CHD, 53.2% had a "low" serum cholesterol level of less than 250 mg/dl (mean, 195.2 mg/dl), 27 .5% had an "intermediate" level of 250-299 mg/dl (mean, 267.4), and 19.3% had a "high" level exceeding 300 mg/dl (mean, 326.8); the ,B for this gender and age group was 0.01309. In the intervention in which we lowered the serum cholesterol level to 240 mg/dl for everyone whose serum cholesterol level was greater than 240 mg/dl, there was a 0.4-mg/dl reduction in the mean serum cholesterol level of the "low" group (generated by those whose levels were 241-249 mg/dl), a 27.4-mg/dl reduction in the "intermediate" group (from 267.4 to 240 mg/dl), and an 86.8-mg/dl decrease in the "high" group (from 326.8 to 240 mg/dl). Using the formula, we calculated the percent reduction in CHD risk for the "low" (0.5% reduction), "intermediate" (30.1% reduction), and "high" (67.9% reduction) groups and took a weighted average of the three (weighted average, 21.6%). Last, we reduced the probabilities of each of the four Disease History Submodel variables mentioned above by that weighted average. The last step in modeling a secondary intervention was to adjust the probability of dying from non-CHD causes (which in the Disease History Submodel, unlike the Demographic-Epidemiologic Submodel, is not done automatically). Here, for each smoking and blood pressure intervention, we took the percent reduction in the non-CHD death rate calculated in the Demographic-Epidemiologic Submodel and applied it to the Disease History Submodel as well.
Calculating Life Expectancy
Persons surviving to age 85 years exit the Coronary Heart Disease Policy Model. To achieve an accurate estimate of life expectancy, it was necessary to add the life expectancy at age 85 years to the surviving 85-year-old persons. Thus, in the baseline run, men reaching age 85 years were credited with an additional 5.0 years of life expectancy, and women were credited with 6.4 years. 20 We used two different methods to estimate life expectancy for interventions. First, to simulate eliminating CHD, we ran the model using a zero probability of developing CHD. We then adjusted the incremental life expectancy for 85-year-old persons by reducing the expected number of deaths each year after age 85 years by the fraction of deaths caused by ischemic heart disease in persons over age 85 years (35% for men, 36% for women)21 and subjecting the cohort of 85-year-old persons to the mortality rate for causes of death other than ischemic heart disease. The derived life expectancy for 85-year-old persons if CHD is eliminated was 6.7 years and 8.6 years for men and women, respectively. Here, we assumed no change in mortality from noncardiac causes. To the extent that persons not dying of CHD might instead die at a more rapid rate from a competing disease, this method may overestimate life expectancy; on the other hand, if CHD were eliminated, there might be a reduction in mortality from related diseases such as cerebrovascular disease, rendering our estimates too low.
In a second method, we calculated life expectancy for a 35-year-old person by adjusting simulated life expectancy by a correction factor to allow a small gain after age 85 years. The correction factor was the ratio of the total life-years accumulated by persons dying between ages 35 and 84 years in the baseline run to the life-years accumulated between ages 35 and 84 years in a given intervention run. Here, a life-year was defined as a year of life after age 35 years; that is, a member of the cohort who dies at age 55 years would get 20 life-years. The baseline life expectancy at age 85 years was multiplied by this ratio, and this adjusted life expectancy for 85-yearold persons was then incorporated into the model to calculate a life expectancy for 35-year-old persons.
When we compared the two methods for estimating life expectancy if CHD is eliminated, the outcomes were nearly identical. Our results for all simulations are presented based on the second approach.
Population-Wide Simulations
Population-wide simulations distribute gains in life expectancy across all 35-year-old personsthose who have the given risk factor and those who do not. We considered the following populationwide interventions: In a given intervention simulation, the risk factor was modified to a certain level and maintained at that level. For example, in one intervention, serum cholesterol level was reduced to 240 mg/dl and not allowed to rise over time. To calculate gains in life expectancy, population-wide interventions were compared with a no-intervention baseline run in which risk factor distributions were allowed to change naturally. That is, in the baseline run, 35-year-old persons assumed the risk factor profile of 45-year-old persons when they turned age 45 years, of 55-yearold persons when they turned age 55 years, and so on. Thus, because smoking is less prevalent in the elderly,15 over time a certain proportion of smokers quit smoking even in the baseline run. Conversely, diastolic blood pressures and serum cholesterol levels are higher in the elderly,15 so that the levels rose accordingly in the baseline run.
At-Risk Individuals Simulations
We considered the following interventions for at- Smoking. 1) Reducing the mean number of cigarettes smoked by 50%; 2) quitting smoking.
Diastolic blood pressure. 1) Reducing diastolic blood pressure to 88 mm Hg if 90-94 mm Hg; 2) reducing diastolic blood pressure to 88 mm Hg if 95-104 mm Hg; 3) reducing diastolic blood pressure to 88 mm Hg if 105 mm Hg or greater.
Relative weight. 1) Reducing weight to ideal body weight if weight exceeds ideal body weight by less than 30%; 2) reducing weight to ideal body weight if weight exceeds ideal body weight by 30% or more.
Whereas the "population-wide" analysis sought to assess the gains from an intervention when compared with the "natural course of events," the "at-risk individuals" analysis was structured to answer a different question: How much life expectancy can a 35-year-old individual having a cardiac risk factor expect to gain if he or she modified that risk factor compared with maintaining that risk factor at its level at age 35 years?
To model the gain for an at-risk individual, we again compared the life expectancy in a baseline run to the life expectancy after a given intervention. Here, however, for each risk factor simulation, we developed a separate baseline run in which the risk factor of interest was "frozen" at its level at age 35 years. For example, to simulate the benefits to smokers of quitting smoking, smokers quit smoking in the intervention, but in the baseline run, they continued to smoke the same number of cigarettes per day until they exited the Demographic-Epidemiologic Submodel. (Diastolic blood pressures and serum cholesterol levels were allowed to rise with age in the baseline smoking and smoking intervention simulations.) Similarly, when determining the benefits of controlling hypertension, we froze (only) their diastolic blood pressures in the baseline run and modified it in the intervention run.
Because assumptions differ between the "population-wide" and "at-risk" individual simulations, population-wide gains cannot be directly mapped onto gains for at-risk individuals. By freezing risk factor levels at their level at age 35 years in baseline "at-risk individuals" simulations, gains from cholesterol and blood pressure interventions are slightly diminished, and gains from smoking cessation are slightly magnified compared with the analogous population-wide interventions. Gains from weight loss are not affected by the differing assumptions.
Sensitivity Analyses
We performed sensitivity analyses on each intervention to determine how varying the P3 coefficients would affect the outcome. For each simulation, the given /3 coefficient was varied from one standard error less than its mean to one standard error greater than its mean. Using a smaller value for the ,B coefficient implies that the risk factor has a smallerthan-expected impact on the incidence of CHD; thus, intervening on that risk factor would yield less impressive gains in life expectancy than those under baseline assumptions. Conversely, a larger ,B coefficient indicates that the risk factor has a more substantial impact on the overall incidence of CHD, meaning that intervening would be more fruitful than those under baseline assumptions. (Table 1 ). The largest estimated gains in male population-wide life expectancy were realized through reducing diastolic blood pressure to 88 mm Hg or eliminating smoking. For women, reducing serum cholesterol level to 200 mg/dl and smoking cessation were projected to have the greatest impacts on population-wide life expectancy. If by reducing risk factors or by other interventions it were possible to eliminate CHD, the model projected that the life expectancies of a 35-year-old man and woman would increase by 3.1 and 3.3 years, respectively. Sensitivity analyses. Reducing the coefficients by one standard error reduced the projected gain in population-wide life expectancy achievable through risk factor intervention. For example, the estimated gain in population-wide life expectancy from eliminating smoking was only 0.5 years for men and 0.4 years for women if the /3 coefficients were one standard error less than the mean Framingham estimates (Table 2) . Conversely, if the actual P3 coefficients for smoking were one standard error greater than the mean, then eliminating smoking would be projected to extend male population-wide life expectancy by 1 from 0.5 to 5.3 years for men and from 0.4 to 6.3 years for women (Table 3 ). Reducing a serum cholesterol level exceeding 300 to 200 mg/dl or reducing a diastolic blood pressure exceeding 105 to 88 mm Hg yielded the greatest benefits. Gains from weight loss were relatively larger for overweight men than for overweight women, whereas quitting smoking was slightly more beneficial for women.
Results
Calibration of the
Sensitivity analyses. Several baseline projections, such as gains from treating borderline hypercholesterolemia, changed little in the sensitivity analyses. Conversely, estimated gains from smoking interventions, cholesterol interventions in those with the highest serum cholesterol levels, and blood pressure interventions in those with the highest diastolic blood pres- sures changed markedly. For example, varying the P coefficients from one standard error less than the mean to one greater than the mean created a range of projected gains for men who quit smoking of 1.3-3.4 years (baseline estimate, 2.3 years) ( Table 4 ). Discussion CHD is the leading cause of death in the United States. It may be surprising, then, to find that even the strictest risk factor modifications-eliminating smoking or reducing body weight, diastolic blood pressure, or serum cholesterol to ideal levels -would yield apparently modest gains in population-wide life expectancy. It is important to realize, however, that in this model, the estimated gains in population-wide life expectancy apply across the entire population, not just to affected individuals. Gains to at-risk individuals can be much more substantial and are directly proportional to the degree that their level exceeds the target.
Although the gains in life expectancy from many of the simulations are modest, risk factor modification can also reduce morbidity. A number of studies56,22 have shown striking reductions in ischemic heart disease events from risk factor modification. Although not the focus of this analysis, a delay or avoidance of coronary events by risk factor reduction10'2 would improve quality of life and reduce medical care expenses independent of any effects on longevity. Intervention may indeed be cost-effective: For example, although national expenditures for treating patients with hypertension would be high, the aggregate net cost per additional quality-adjusted year of life can be as low as several thousand dollars, depending on age and pretreatment diastolic blood pressure.1"'23 Comparison With Prior Studies At least four previous analyses have estimated the impact of risk factors or CHD per se on life expectancy. The Centers for Disease Control recently calculated that smoking exacts a toll of 0.015 years from the average population-wide life expectancy. 24 Taylor and colleagues,25 who performed an analogous analysis of gains in life expectancy for affected individuals from risk factor modification, found that cholesterol reduction could generally achieve a gain in life expectancy of weeks to months for people with hypercholesterolemia. Persons at highest risk, defined as having a systolic blood pressure, cigarette smoking habit, and total serum cholesterol level each at the 90th percentile and a high density lipoprotein cholesterol level at the 10th percentile for their age and gender, were estimated to live 2-11 months longer (depending on age and gender) by reducing their serum cholesterol levels by 6.7% and to live 5-29 months longer by reducing it by 20%. By comparison, they projected gains of 23-70 months from quitting smoking and of [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] months from reducing systolic blood pressure by 14.3%. Taylor and coworkers25 did not consider gains from weight reduction.
Cohen and Lee26 estimated that heart disease shortens male life expectancy by 6.3 years and female life expectancy by 5.4 years. They also estimated that smoking costs the male smoker 5.9-6.2 years and the female smoker 1.2-2.2 years of life expectancy. Being 30% overweight was projected to shorten one's life by 3.6 years, and being 20% overweight was projected to shorten one's life by 2.5 years. Finally, Tsai and colleagues27 projected that eliminating all cardiovascular disease would prolong the life expectancy of 35-year-old individuals by 12.9 years.
Certain projections from our model are quite close to previous projections. For example, our projected gains from control of hypercholesterolemia and hypertension agree with those of Taylor and coworkers. 25 Our projected gains for female smokers are in the same range as Cohen and Lee's26 estimates. Meanwhile, there are discrepancies with other projections. Cohen and Lee26 and Tsai and colleagues27 project larger gains from the elimination of CHD than do we. The differences may be explained in part by the fact that their projections were based on data from an era when CHD was more prevalent and treatments were fewer; also, Tsai and coauthors27 considered gains from eliminating all cardiovascular disease, not just CHD. In contrast, the Centers for Disease Control24 projected smaller losses in population-wide life expectancy from smoking than does the Coronary Heart Disease Policy Model. The difference between their estimate and ours may emanate from their consideration of the entire population, children as well as adults.
Limitations
Like any forecasting tool, our model has certain limitations. First, for simplicity, the Coronary Heart Disease Policy Model assumes that risk factors are distributed independently of each other; that is, they are conditional only on age and gender. Furthermore, the model assumes that intervening on one risk factor does not affect other risk factors. In actuality, reduction in weight could also improve serum cholesterol level and diastolic blood pressure, whereas reductions in smoking may lead to weight gain. Thus, the assumption of independence of risk factors could underestimate or overestimate the impact of any single risk factor intervention.
A major problem of such an analysis is that the coefficients of risk are derived from population-based studies. Because of misclassification of both exposure status and to a lesser extent outcome status, the coefficients likely underestimate the true relation between risk factors and disease.28 Underestimating relative risk results in a corresponding underestimation of the benefits of intervention. The sensitivity analyses demonstrate the effect of varying the relative risk on the projected gain; some projections are affected to a greater degree than others (Tables 2  and 4 
)
A third limitation is that we applied cross-sectional data longitudinally. That is, in the model, the cohort of 35-year-old persons has CHD incidence rates unique to its 10-year age range. When the cohort turns 45 years, it adopts new CHD incidence rates, but these are based on patients who would have been 45 years old in 1990. Of course, one cannot know the true incidence rates until our starting cohort itself turns 45 years in the year 2000. Our model also assumes an immediate benefit from risk factor intervention, whereas in reality, there may be a short delay in assuming normal risk.
For example, the risk of CHD attributable to smoking declines by 50% 1 year after quitting,29 and it takes perhaps 3 years for a reduction in cholesterol level to yield its full benefit.5,25,30-32 Yet in risk factor intervention modeling, it is advantageous to emphasize the current risk factor profile over the historical profile.22 Moreover, we tested the effect of a lag period in a complementary analysis of hypercholesterolemia: After 25 years, the results were nearly identical to the analysis having no lag period. 10 The accuracy of the Coronary Heart Disease Policy Model's projections is partly dependent on the accuracy of US vital statistics data. Those data indicate that mortality from ischemic heart disease (ICD codes 410-414)33 has declined since 1980, yet much of this decline is offset by rises in deaths from cardiac arrest and congestive heart failure.34 Thus, changes in coding may account for some of the apparent decline in ischemic heart disease mortality.
In addition, recent data from the Health Interview Study indicate that the prevalence of ischemic heart disease has increased by more than 10% in the last decade.35 This trend, in an era of improving coronary risk factors, is probably explained by more aggressive and earlier diagnosis of CHD and a prolonged expectancy of persons with CHD as opposed to an increase in atherosclerosis. In future updates of the model, we hope to capture such changing risk factor distributions and prevalences, along with the projected impact of new therapies such as thrombolysis and percutaneous transluminal coronary angioplasty.
Conclusion
Planning agencies and payors may find projected population-wide gains useful as a bench mark for what may be worth targeting on a national level. Previous analyses found that eliminating cancer -a veritable pie in the skycould extend average population-wide life expectancy at birth by 2.3-2.7 years.26,36 Our analysis shows that eliminating CHD, an equally impossible task, would prolong the life of the average 35-year-old by a little over 3 years. The single risk factor interventions considered would prolong population-wide life expectancy by 0.2-1.1 years.
Health care providers and patients may be more interested in potential gains for the individual at risk. Here, gains can be more substantial and are a function of the preintervention and postintervention risk factor level. It is up to the individual and to society to weigh the potential gains against the sacrifices.
